Comments Regarding Quantitative Labeling of Sodium, Potassium, and Phosphorus for OTC and Prescription Drug Products Share page: Docket Number: FDA-2021-D-0528 Download Document Issues: OTC Medicines Other Issues Labeling Quality Related Posts Press Releases and Statements CHPA Applauds OMUFA Introduction, Calls for Inclusion of GRASE and Sunscreen Reforms Jul 2, 2025 Press Releases and Statements CHPA Applauds Bipartisan Bill to Streamline Access to Next-Generation Sunscreens in the U.S. Jun 4, 2025 2025 Mid-Year Impact Report Jun 20, 2025